secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001104659-24-070450
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio Buntanetap Phase II/III shows statistically significant efficacy in APOE4 Alzheimer's patients
--------------------------------------------------------------------------------

- In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.
- APOE4 carriers on 15mg dose achieved -3.15 point improvement in ADAS-Cog11 scores.
- Buntanetap had no ARIA or serious drug-related TEAEs; safety comparable in carriers and non-carriers.
- Study included 159 APOE4 carriers (33 homozygotes) and 159 non-carriers.
- Company plans 18-month Phase III trial in biomarker-positive early AD patients under FDA guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/0001104659-24-070450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/tm2416963d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-070450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer